Literature DB >> 12958155

Aberrant A2A receptor function in peripheral blood cells in Huntington's disease.

Katia Varani1, Maria P Abbracchio, Milena Cannella, Giuliana Cislaghi, Patrizia Giallonardo, Caterina Mariotti, Elena Cattabriga, Flaminio Cattabeni, Pier Andrea Borea, Ferdinando Squitieri, Elena Cattaneo.   

Abstract

A2A adenosine receptors specifically found on striatal medium spiny neurons play a major role in sensory motor function and may also be involved in neuropsychiatric and neurodegenerative disorders. One hypothesis concerning Huntington's disease (HD) proposes that an imbalance of the cortico-striatal pathway, due to the mutation in the HD gene, leads to striatal vulnerability. An A2A receptor dysfunction has been previously demonstrated in striatal cells engineered to express mutant huntingtin. Here we tested whether a similar dysfunction (i.e., the binding and functional parameters of A2A adenosine receptors) is present in peripheral blood cells (platelets, lymphocytes, and neutrophils) of subjects carrying the mutant gene. This study involved 48 heterozygous and three homozygous patients compared with 58 healthy subjects. Moreover, we selected seven at-risk mutation carriers. A2A receptor density and function are substantially increased in peripheral blood cells from both patients and subjects at the presymptomatic stage. In the neutrophils of the three homozygous HD subjects receptor dysfunction was higher than in heterozygotes. These data indicate the existence of an aberrant A2A receptor phenotype in the peripheral blood cells of subjects carrying the HD mutation. Future studies will assess whether this parameter can be exploited as a peripheral biomarker of Huntington's disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12958155     DOI: 10.1096/fj.03-0079fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  19 in total

1.  In vivo evaluation of [11C]preladenant positron emission tomography for quantification of adenosine A2A receptors in the rat brain.

Authors:  Xiaoyun Zhou; Shivashankar Khanapur; Johan R de Jong; Antoon Tm Willemsen; Rudi Ajo Dierckx; Philip H Elsinga; Erik Fj de Vries
Journal:  J Cereb Blood Flow Metab       Date:  2016-07-20       Impact factor: 6.200

2.  Mutant huntingtin impairs vesicle formation from recycling endosomes by interfering with Rab11 activity.

Authors:  Xueyi Li; Clive Standley; Ellen Sapp; Antonio Valencia; Zheng-Hong Qin; Kimberly B Kegel; Jennifer Yoder; Laryssa A Comer-Tierney; Miguel Esteves; Kathryn Chase; Jonathan Alexander; Nicholas Masso; Lindsay Sobin; Karl Bellve; Richard Tuft; Lawrence Lifshitz; Kevin Fogarty; Neil Aronin; Marian DiFiglia
Journal:  Mol Cell Biol       Date:  2009-09-14       Impact factor: 4.272

3.  HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity.

Authors:  Virginia B Mattis; Colton Tom; Sergey Akimov; Jasmine Saeedian; Michael E Østergaard; Amber L Southwell; Crystal N Doty; Loren Ornelas; Anais Sahabian; Lindsay Lenaeus; Berhan Mandefro; Dhruv Sareen; Jamshid Arjomand; Michael R Hayden; Christopher A Ross; Clive N Svendsen
Journal:  Hum Mol Genet       Date:  2015-03-03       Impact factor: 6.150

4.  Functional changes in postsynaptic adenosine A(2A) receptors during early stages of a rat model of Huntington disease.

Authors:  Marco Orrú; Janaina Menezes Zanoveli; César Quiroz; Huu Phuc Nguyen; Xavier Guitart; Sergi Ferré
Journal:  Exp Neurol       Date:  2011-08-16       Impact factor: 5.330

Review 5.  Genetics and neuropathology of Huntington's disease.

Authors:  Anton Reiner; Ioannis Dragatsis; Paula Dietrich
Journal:  Int Rev Neurobiol       Date:  2011       Impact factor: 3.230

6.  The Novel Alpha-2 Adrenoceptor Inhibitor Beditin Reduces Cytotoxicity and Huntingtin Aggregates in Cell Models of Huntington's Disease.

Authors:  Elisabeth Singer; Lilit Hunanyan; Magda M Melkonyan; Jonasz J Weber; Lusine Danielyan; Huu Phuc Nguyen
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-12

7.  Neuronal adenosine A2A receptor overexpression is neuroprotective towards 3-nitropropionic acid-induced striatal toxicity: a rat model of Huntington's disease.

Authors:  Maria Rosaria Domenici; Valentina Chiodi; Mirko Averna; Monica Armida; Antonella Pèzzola; Rita Pepponi; Antonella Ferrante; Michael Bader; Kjell Fuxe; Patrizia Popoli
Journal:  Purinergic Signal       Date:  2018-05-16       Impact factor: 3.765

Review 8.  Neuroprotection for Huntington's disease: ready, set, slow.

Authors:  Steven M Hersch; H Diana Rosas
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

9.  Platelet-derived extracellular vesicles in Huntington's disease.

Authors:  Hélèna L Denis; Jérôme Lamontagne-Proulx; Isabelle St-Amour; Sarah L Mason; Andreas Weiss; Sylvain Chouinard; Roger A Barker; Eric Boilard; Francesca Cicchetti
Journal:  J Neurol       Date:  2018-09-12       Impact factor: 4.849

10.  Normal platelet mitochondrial complex I activity in Huntington's disease.

Authors:  William J Powers; Richard H Haas; Thuy Le; Tom O Videen; Tamara Hershey; Lori McGee-Minnich; Joel S Perlmutter
Journal:  Neurobiol Dis       Date:  2007-05-05       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.